{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:18:53Z","timestamp":1768889933732,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019921","name":"Geistlich Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clnu.2022.07.025","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T02:22:41Z","timestamp":1659234161000},"page":"2178-2184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Taurolidine-related adverse events in patients on home parenteral nutrition frequently indicate catheter-related problems"],"prefix":"10.1016","volume":"41","author":[{"given":"J.W.","family":"Korzilius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.E.L.M.","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.A.","family":"Wanten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clnu.2022.07.025_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clnu.2016.01.020","article-title":"ESPEN guidelines on chronic intestinal failure in adults","volume":"35","author":"Pironi","year":"2016","journal-title":"Clin Nutr"},{"issue":"6","key":"10.1016\/j.clnu.2022.07.025_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clnu.2020.03.005","article-title":"ESPEN guideline on home parenteral nutrition","volume":"39","author":"Pironi","year":"2020","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnu.2022.07.025_bib3","doi-asserted-by":"crossref","first-page":"d1447","DOI":"10.1136\/bmj.d1447","article-title":"Managing adult patients who need home parenteral nutrition","volume":"342","author":"Wanten","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clnu.2022.07.025_bib4","first-page":"67","article-title":"[Antibacterial therapy of purulent peritonitis: a prospective randomized study on the effects of antibiotics and taurolin, a new chemotherapeutic and antiendotoxic agent (author\u2019s transl)]","author":"Linder","year":"1980","journal-title":"Chir Forum Exp Klin Forsch"},{"issue":"1\u20132","key":"10.1016\/j.clnu.2022.07.025_bib5","first-page":"143","article-title":"[A new surgical lavage]","volume":"45","author":"Buhler","year":"1978","journal-title":"Helv Chir Acta"},{"issue":"12","key":"10.1016\/j.clnu.2022.07.025_bib6","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1093\/jac\/dku281","volume":"69","author":"Luther","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.clnu.2022.07.025_bib7","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1600-0463.2012.02910.x","article-title":"Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin","volume":"120","author":"Handrup","year":"2012","journal-title":"Apmis"},{"issue":"6","key":"10.1016\/j.clnu.2022.07.025_bib8","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1128\/AAC.46.6.1674-1679.2002","article-title":"Antimicrobial activity of a novel catheter lock solution","volume":"46","author":"Shah","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.clnu.2022.07.025_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2672.1979.tb02586.x","article-title":"The anti-endotoxin activity of Taurolin in experimental animals","volume":"46","author":"Pfirrmann","year":"1979","journal-title":"J\u00a0Appl Bacteriol"},{"issue":"6","key":"10.1016\/j.clnu.2022.07.025_bib10","first-page":"842","article-title":"The in\u00a0vitro and in\u00a0vivo activity of taurolin against anaerobic pathogenic organisms","volume":"145","author":"Browne","year":"1977","journal-title":"Surg Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.clnu.2022.07.025_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clnu.2014.04.023","article-title":"Microbiocidal effects of various taurolidine containing catheter lock solutions","volume":"34","author":"Olthof","year":"2015","journal-title":"Clin Nutr"},{"issue":"3","key":"10.1016\/j.clnu.2022.07.025_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3945\/ajcn.117.158964","article-title":"Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial","volume":"106","author":"Tribler","year":"2017","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.clnu.2022.07.025_bib13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/apt.14904","article-title":"Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition","volume":"48","author":"Wouters","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clnu.2022.07.025_bib14","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.clnu.2018.09.020","article-title":"Clinical outcomes of home parenteral nutrition patients using taurolidine as catheter lock: a long-term cohort study","volume":"38","author":"Wouters","year":"2019","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.clnu.2022.07.025_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clnu.2009.12.005","article-title":"Taurolidine lock is highly effective in preventing catheter-related bloodstream infections in patients on home parenteral nutrition: a heparin-controlled prospective trial","volume":"29","author":"Bisseling","year":"2010","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.clnu.2022.07.025_bib16","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.clnu.2018.08.005","article-title":"Repair of damaged central venous catheters is safe and doubles catheter survival: a home parenteral nutrition patient cohort study","volume":"38","author":"Wouters","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnu.2022.07.025_bib17","series-title":"Common terminology criteria for adverse events. Version 5.0","author":"Services UDoHH","year":"2017"},{"issue":"12","key":"10.1016\/j.clnu.2022.07.025_bib18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.clnu.2022.07.025_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clnu.2005.02.001","article-title":"Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections","volume":"24","author":"Jurewitsch","year":"2005","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.clnu.2022.07.025_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5301\/jva.5000168","article-title":"Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition","volume":"14","author":"Al-Amin","year":"2013","journal-title":"J\u00a0Vasc Access"},{"issue":"3","key":"10.1016\/j.clnu.2022.07.025_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0148607114525804","article-title":"Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial","volume":"39","author":"Klek","year":"2015","journal-title":"JPEN - J Parenter Enter Nutr"},{"issue":"4","key":"10.1016\/j.clnu.2022.07.025_bib22","first-page":"761","article-title":"Clinical and economic impact of the taurolidine lock on home parenteral nutrition","volume":"35","author":"Arnoriaga Rodr\u00edguez","year":"2018","journal-title":"Nutr Hosp"},{"issue":"11","key":"10.1016\/j.clnu.2022.07.025_bib23","doi-asserted-by":"crossref","first-page":"e111216","DOI":"10.1371\/journal.pone.0111216","article-title":"Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions","volume":"9","author":"Olthof","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clnu.2022.07.025_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jhin.2021.10.022","article-title":"The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis","volume":"123","author":"van den Bosch","year":"2022","journal-title":"J\u00a0Hosp Infect"},{"issue":"11","key":"10.1016\/j.clnu.2022.07.025_bib25","article-title":"Locked away-prophylaxis and management of catheter related thrombosis in hemodialysis","volume":"10","author":"Szyma\u0144ska","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.clnu.2022.07.025_bib26","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1128\/JCM.39.6.2294-2297.2001","article-title":"Biofilm formation by gram-negative bacteria on central venous catheter connectors: effect of conditioning films in a laboratory model","volume":"39","author":"Murga","year":"2001","journal-title":"J\u00a0Clin Microbiol"},{"issue":"6","key":"10.1016\/j.clnu.2022.07.025_bib27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/0091270007299929","article-title":"The pharmacokinetics of taurolidine metabolites in healthy volunteers","volume":"47","author":"Gong","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.clnu.2022.07.025_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0378-5173(89)90112-9","article-title":"Assay procedures for Taurolin solutions using pre-column derivatisation and high-performance liquid chromatography with fluorescence detection","volume":"49","author":"Woolfson","year":"1989","journal-title":"Int J Pharmaceutics"},{"issue":"11 Pt 1","key":"10.1016\/j.clnu.2022.07.025_bib29","first-page":"953","article-title":"Structural investigation of a new organic antiseptic: taurolidine A spectroscopic study of its stability and equilibria in various solvents","volume":"29","author":"Erb","year":"1983","journal-title":"Talanta"},{"issue":"1","key":"10.1016\/j.clnu.2022.07.025_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CMR.0b013e328341442d","article-title":"The antibacterial substance, taurolidine in the second\/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study","volume":"21","author":"Imhof","year":"2011","journal-title":"Melanoma Res"},{"issue":"9","key":"10.1016\/j.clnu.2022.07.025_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.cad.0000176502.40810.b0","article-title":"Taurolidine-a new drug with anti-tumor and anti-angiogenic effects","volume":"16","author":"Jacobi","year":"2005","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.clnu.2022.07.025_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1477-7819-4-34","article-title":"Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case","volume":"4","author":"Braumann","year":"2006","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.clnu.2022.07.025_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.204","article-title":"Taurolidine and congeners activate hTRPA1 but not hTRPV1 channels and stimulate CGRP release from mouse tracheal sensory nerves","volume":"4","author":"Kichko","year":"2016","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.clnu.2022.07.025_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2020.08.398","article-title":"Novel basophil activation test in the diagnosis of povidone anaphylaxis","volume":"126","author":"Murthee","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.clnu.2022.07.025_bib35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.anai.2021.01.030","article-title":"Repeated idiopathic anaphylaxis caused by povidone","volume":"126","author":"Bruusgaard-Mouritsen","year":"2021","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561422002692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561422002692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T01:08:52Z","timestamp":1759367332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561422002692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0261561422002692"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2022.07.025","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taurolidine-related adverse events in patients on home parenteral nutrition frequently indicate catheter-related problems","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2022.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}